Filing Analysis
DocGo Inc. has entered into a definitive merger agreement to acquire Hicuity Health, Inc. via its subsidiary, Ambulnz. The transaction is structured as a deemed liquidation event where the entire consideration is payable to Hicuity's Series F Preferred Stockholders, effectively wiping out all other equity holders.
🚩 Red Flags
- Extreme dilution/wipeout of existing Hicuity equity holders due to the 'Deemed Liquidation Event' structure.
- Complex earnout structure for the Series F holders involving market capitalization thresholds.
- The acquisition involves assuming existing indebtedness of the target company.
- The consulting agreement structure (management fee based on gross revenue less expenses) is highly non-standard and suggests potential operational instability in the target.
📋 Key Facts
- DocGo's subsidiary, Ambulnz, will merge with Hicuity Health, Inc., with Hicuity surviving as a wholly owned subsidiary.
- Merger consideration consists of 2.0% of DocGo common stock (closing) and up to 3.5% (earnout shares) subject to market cap thresholds.
- The transaction is a 'Deemed Liquidation Event'; all Hicuity shares/options/warrants except Series F Preferred Stock will be cancelled for no consideration.
- Ambulnz will assume Hicuity's existing debt with Perceptive Credit Holdings IV, LP.
- Perceptive Credit Holdings IV, LP has committed up to $50,000,000 in new senior secured term loans to support the transaction.
- Ambulnz and Hicuity entered a Consulting Services Agreement where Ambulnz will manage Hicuity's operations and fund operating expenses in exchange for a revenue-based fee.
DocGo Inc. has received a notification from Nasdaq granting an extension until January 25, 2027, to regain compliance with the minimum bid price requirement ($1.00 per share). The company is considering a reverse stock split to meet these requirements.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement.
- Explicit mention of a potential reverse stock split to regain compliance.
- Risk of continued non-compliance despite the extension.
📋 Key Facts
- Nasdaq granted an additional 180-day compliance period ending January 25, 2027.
- Compliance requires the closing bid price to be at least $1.00 per share for 10 consecutive business days.
- Stockholders previously approved a range of reverse stock split ratios (1-for-5 through 1-for-10) on June 16, 2026.
DocGo Inc. has extended the expiration date of its existing share repurchase program from June 30, 2026, to December 31, 2026. The company maintains a total authorization of up to $26 million for these repurchases.
📋 Key Facts
- Expiration date extended from June 30, 2026, to December 31, 2026.
- Total repurchase authorization remains at $26 million.
- Repurchases may be conducted via open market, private transactions, Rule 10b5-1 plans, or accelerated share repurchase programs.
- Funding sources include existing cash, future cash flow, or proceeds from borrowings/debt offerings.
DocGo Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Most notably, stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-10, to be determined by the Board.
🚩 Red Flags
- Approval of a reverse stock split is a major red flag for micro-cap companies, often indicating a struggle to maintain minimum exchange listing price requirements.
- Significant 'Votes Withheld' for director nominees (e.g., 25.1M withheld for James M. Travers), suggesting shareholder dissatisfaction.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio range of 1-for-5 to 1-for-10.
- Vina Leite and James M. Travers were elected as Class II directors.
- Executive compensation was approved on a non-binding, advisory basis.
- Urish Popeck & Co., LLC was ratified as the independent registered public accounting firm for 2026.
- The 'Corporate Opportunity Amendment' and 'Officer Exculpation Amendment' were both rejected by stockholders.
DocGo Inc. announced its financial results for the first quarter ended March 31, 2026. The company furnished a press release and non-GAAP financial reconciliations, specifically highlighting adjusted gross margin.
📋 Key Facts
- Earnings results for the quarter ended March 31, 2026, were announced on May 11, 2026.
- The company reported non-GAAP 'adjusted gross margin' and provided a reconciliation to GAAP measures in Exhibit 99.2.
- A conference call was held on May 11, 2026, at 5:00 p.m. ET to discuss the results.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
DocGo Inc. announced the resignation of director Dr. Stephen K. Klasko and a subsequent board reshuffle, including the appointment of Michael Burdiek as independent Chair. Crucially, the company also formed a special committee dedicated to identifying cost reductions and corporate efficiencies to accelerate profitability.
🚩 Red Flags
- The formation of a special committee specifically for 'cost reduction' and 'efficiencies' often signals internal or external pressure regarding the company's burn rate or path to profitability.
- Board reshuffling occurring simultaneously with the initiation of cost-cutting measures.
📋 Key Facts
- Dr. Stephen K. Klasko to resign from the Board effective June 16, 2026, to accept a new healthcare leadership role.
- Michael Burdiek appointed as independent Chair of the Board, effective June 16, 2026.
- Jim Travers appointed to the Audit and Compliance Committee and the Nominating and Corporate Governance Committee.
- A special committee was formed on April 21, 2026, consisting of Vina Leite, Ira Smedra, and Michael Burdiek (Chair).
- The special committee's mandate is to identify corporate efficiencies and cost reduction opportunities to accelerate profitability.
DocGo Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The company scheduled a conference call for March 16, 2026, to discuss these results and provided reconciliations for non-GAAP financial measures.
📋 Key Facts
- Earnings results cover the quarter and fiscal year ended December 31, 2025.
- The company reported the use of a non-GAAP financial measure, 'adjusted gross margin'.
- A conference call and webcast were scheduled for 5:00 p.m. Eastern Time on March 16, 2026.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Non-GAAP Financial Information).
DocGo Inc. received a notice from Nasdaq stating it is in violation of the minimum bid price requirement ($1.00 per share) based on stock performance between December 9, 2025, and January 23, 2026. The company has a 180-day window to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price of $1.00
- Explicit mention of a potential reverse stock split to cure deficiency
📋 Key Facts
- Nasdaq notified the company of non-compliance with Listing Rule 5550(a)(2) regarding the $1.00 minimum bid requirement.
- The deficiency period began following a review of stock prices from Dec 9, 2025, to Jan 23, 2026.
- The company has until July 27, 2026, to regain compliance by maintaining a $1.00 closing bid for at least ten consecutive business days.
- A second 180-day compliance period may be available if certain market value and listing standards are met.
- The company explicitly mentioned that a reverse stock split is a potential option being evaluated to regain compliance.
DocGo Inc. has extended the expiration date of its existing $26 million share repurchase program from December 31, 2025, to June 30, 2026.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Board approved extension of Repurchase Program expiration: Dec 31, 2025 $\rightarrow$ June 30, 2026.
- Total authorized repurchase amount remains $26 million.
- Repurchases may be funded via cash, future cash flow, or proceeds from borrowings/debt offerings.
- Filing made under Item 7.01 (Regulation FD Disclosure).
DocGo Inc. issued an 8-K to announce its earnings results for the fiscal quarter ended September 30, 2025. The filing includes a press release and non-GAAP financial measures such as adjusted gross margin and adjusted EBITDA contribution margin.
📋 Key Facts
- Earnings results announced for the quarter ended September 30, 2025.
- Management to discuss adjusted gross margin and adjusted EBITDA contribution margin during conference call.
- Conference call scheduled for November 10, 2025, at 5:00 p.m. ET.
DocGo Inc., through its subsidiary Ambulnz Holdings, LLC, has entered into a definitive agreement to acquire SteadyMD, Inc. for an aggregate purchase price of up to $25 million.
🚩 Red Flags
- The transaction includes a significant contingent earn-out component (50% of total potential value), which introduces uncertainty regarding the final cost and future dilution if equity is chosen.
📋 Key Facts
- Acquisition of SteadyMD, Inc. by Ambulnz Holdings, LLC (a DocGo subsidiary).
- Total transaction value is up to $25 million.
- Consideration includes $12.5 million in cash at closing and up to $12.5 million in contingent earn-out payments.
- The earn-out can be paid in either cash or equity at the Company's election.
- Transaction involves a merger between STMD Merger Company, LLC and SteadyMD, Inc., effective October 20, 2025.
DocGo Inc., through its subsidiary Ambulnz Holdings, LLC, has completed the acquisition of SteadyMD, Inc. for an aggregate potential consideration of up to $25 million.
🚩 Red Flags
- The deal includes a significant contingent earn-out component (50% of total potential value), which introduces uncertainty regarding final acquisition costs and integration success.
📋 Key Facts
- Acquisition of SteadyMD, Inc. by DocGo's subsidiary, Ambulnz Holdings, LLC.
- Total transaction value: Up to $25 million.
- Closing purchase price: $12.5 million in cash (subject to customary adjustments).
- Contingent earn-out: Up to $12.5 million payable in cash or equity based on performance conditions.
- Transaction closed via merger with STMD Merger Company, LLC.
DocGo Inc. issued an 8-K to announce its earnings results for the quarter ended June 30, 2025. The filing includes a press release and non-GAAP financial measures related to adjusted gross margins for specific business segments.
📋 Key Facts
- Earnings results announced for the quarter ending June 30, 2025.
- Management will report segment-specific adjusted gross margin for Mobile Health Services and Transportation.
- Conference call/webcast scheduled for August 7, 2025, at 5:00 p.m. ET.
- The filing includes non-GAAP financial information in Exhibit 99.2.
DocGo Inc. held its 2025 Annual Meeting of Stockholders on June 17, 2025. The meeting resulted in the election of three Class I directors and the ratification of the company's independent auditor.
🚩 Red Flags
- Shareholders rejected two significant charter amendments: a waiver of corporate opportunities and officer exculpation.
- The rejection of an 'Officer Exculpation Amendment' suggests shareholder dissatisfaction or concern regarding management liability protections.
📋 Key Facts
- Three Class I director nominees (Lee Bienstock, Ely D. Tendler, and Ira Smedra) were elected to serve until 2028.
- Stockholders approved the non-binding advisory compensation of named executive officers.
- The 'Corporate Opportunity Amendment' to the Charter was NOT approved by stockholders.
- The 'Officer Exculpation Amendment' to the Charter was NOT approved by stockholders.
- Urish Popeck & Co., LLC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
DocGo Inc. has extended the expiration date of its existing $26 million share repurchase program from June 30, 2025, to December 31, 2025.
📋 Key Facts
- Repurchase Program extension: From June 30, 2025, to December 31, 2025.
- Total authorized repurchase amount remains at $26 million.
- The program may be funded via cash, future cash flow, or proceeds from borrowings/debt offerings.
DocGo Inc. filed an 8-K to announce its earnings results for the quarter ended March 31, 2025. The filing includes a press release and non-GAAP financial information regarding adjusted gross margin.
📋 Key Facts
- Earnings results announced for the quarter ended March 31, 2025.
- Management to report 'adjusted gross margin' as a non-GAAP financial measure.
- Conference call/webcast scheduled for May 8, 2025, at 5:00 p.m. ET.
- Exhibits include the press release (99.1) and non-GAAP reconciliation (99.2).
DocGo Inc. issued an 8-K to announce its earnings results for the quarter and fiscal year ended December 31, 2024. The filing includes a press release and non-GAAP financial measures regarding adjusted gross margin.
📋 Key Facts
- Earnings results announced for the quarter and year ended December 31, 2024.
- Management to report 'adjusted gross margin' as a non-GAAP financial measure.
- Conference call/webcast scheduled for February 27, 2025, at 5:00 p.m. ET.
DocGo Inc. has extended the expiration date of its existing $26 million share repurchase program from December 31, 2024, to June 30, 2025.
🚩 Red Flags
- Potential for dilution if repurchases are funded through new debt or equity offerings as noted in the filing text.
📋 Key Facts
- Board of Directors approved an extension of the Repurchase Program on December 20, 2024.
- The new expiration date for the program is June 30, 2025.
- The total authorized repurchase amount remains $26 million in common stock.
- Repurchases may be funded via cash, future cash flow, or debt offerings/borrowings.
DocGo Inc. filed an 8-K to announce its quarterly earnings results for the period ended September 30, 2024. The filing includes a press release and non-GAAP financial reconciliations.
📋 Key Facts
- Earnings results announced for the quarter ended September 30, 2024.
- Management to report 'adjusted gross margin' as a non-GAAP financial measure.
- Conference call scheduled for November 7, 2024, at 5:00 p.m. ET.
DocGo Inc. announced a leadership transition in its Board of Directors, involving the appointment of Dr. Stephen K. Klasko as the new independent Chair and the resignation of Steven Katz. Mr. Katz will remain as a consultant through year-end 2024 to facilitate the transition.
🚩 Red Flags
- Departure of the Board Chair (though stated as non-disagreement, leadership turnover in micro-caps often warrants scrutiny).
📋 Key Facts
- Dr. Stephen K. Klasko appointed as Class III director and independent Chair, effective October 1, 2024.
- Steven Katz resigned as Director and Chair of the Board, effective October 1, 2024; resignation was not due to any disagreement with the company.
- Dr. Klasko's compensation includes a $500,000 one-time stock option grant (vesting in one year) and $300,000 annual cash compensation.
- Steven Katz will serve as a consultant through December 31, 2024, receiving $2,500/month plus hourly fees for work exceeding five hours/month.
- Dr. Klasko joins the Audit and Compliance Committee and the Nominating and Corporate Governance Committee.
DocGo Inc. issued an 8-K to announce its earnings results for the second quarter ended June 30, 2024. The filing includes a press release and non-GAAP financial information regarding adjusted gross margin.
📋 Key Facts
- Earnings results for the quarter ended June 30, 2024 were announced on August 7, 2024.
- The company provided non-GAAP financial measures, specifically 'adjusted gross margin'.
- A conference call and webcast was scheduled for August 7, 2024, at 5:00 p.m. ET to discuss the results.
DocGo Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 18, 2024. The meeting included elections for two Class III directors and advisory votes regarding executive compensation and voting frequency.
📋 Key Facts
- Annual Meeting held on June 18, 2024.
- Steven Katz elected to the Board of Directors (38,834,460 votes for).
- Michael Burdiek elected to the Board of Directors (50,660,416 votes for).
- Say-on-Pay advisory vote approved with 38,170,534 votes in favor.
- Stockholders voted for an annual frequency for future advisory compensation votes (52,486,733 votes for).
- Ratification of Urish Popeck & Co., LLC as independent registered public accounting firm for the fiscal year ending December 31, 2024.
DocGo Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended March 31, 2024. The filing is a standard disclosure of results of operations and financial condition.
📋 Key Facts
- The company issued a press release on May 8, 2024, regarding earnings results for the quarter ended March 31, 2024.
- The information was furnished under Item 2.02 of Form 8-K and is not considered 'filed' for purposes of the Exchange Act.
- Chief Financial Officer Norman Rosenberg signed the report.
DocGo Inc. reported a cybersecurity incident involving unauthorized access to certain systems. The breach resulted in the acquisition of protected health information (PHI) from a limited number of healthcare records within its U.S.-based ambulance transportation business.
🚩 Red Flags
- Unauthorized access to Protected Health Information (PHI) carries significant regulatory and litigation risk.
- Potential for reputational damage and increased scrutiny from healthcare regulators.
- Ongoing investigation may uncover a larger scope of data exfiltration than currently reported.
📋 Key Facts
- Unauthorized activity was detected and contained by the company.
- The breach involved data/protected health information (PHI) from a 'limited number' of records in the U.S. ambulance transportation division.
- No other business lines were affected according to current findings.
- As of May 7, 2024, no evidence of continued unauthorized activity was found.
- The company is initiating legal notifications as required by law.
DocGo Inc.'s subsidiary, Rapid Reliable Testing NY, LLC (RRT), has extended its service agreement with the New York City Department of Housing Preservation and Development (HPD). The extension covers services for asylum seekers through December 31, 2024.
📋 Key Facts
- Subsidiary RRT entered into a letter agreement with NYC HPD on April 8, 2024.
- The contract extension period is from May 5, 2024, to December 31, 2024.
- Services include provision of services for hotels outside the five boroughs of NYC and transition support for a new provider within the five boroughs.
DocGo Inc. announced a leadership transition in its Board of Directors, including the retirement of Chair Stan Vashovsky and the appointment of Lee Bienstock to the Board effective April 1, 2024.
🚩 Red Flags
- Succession of leadership in the Board Chair position can sometimes signal internal shifts, though no disagreement was cited.
📋 Key Facts
- Stan Vashovsky will step down as Director and Chair of the Board on March 31, 2024.
- Lee Bienstock appointed as a Class I director, effective April 1, 2024.
- Steven Katz to succeed Vashovsky as Chair of the Board, effective April 1, 2024.
- Vashovsky will serve as a consultant until March 31, 2025 under a separation and consulting agreement.
- Consulting compensation includes quarterly equity grants with a fair value of approximately $35,000 per quarter.
DocGo Inc. filed an 8-K to announce its earnings results for the quarter and fiscal year ended December 31, 2023. The filing serves as a formal announcement of the release of financial performance data via press release.
📋 Key Facts
- Earnings results announced for the quarter and year ended December 31, 2023.
- Filing date: February 28, 2024.
- The information is furnished under Item 2.02 but is not considered 'filed' for purposes of liability under the Exchange Act.
DocGo Inc. entered into an amendment to its existing credit agreement with Citibank, N.A. to allow for a share repurchase program. Additionally, the company announced a new $36 million share repurchase program spanning through July 2024.
🚩 Red Flags
- Repurchases may be funded by 'proceeds of borrowings or debt offerings', which can indicate a preference for using leverage rather than organic cash flow to support share price.
📋 Key Facts
- Entered into an Amendment to the November 1, 2022 Credit Agreement on January 30, 2024.
- Amendment allows for repurchases of common stock up to an aggregate of $40 million (including prior program amounts).
- Board approved a new share repurchase program of up to $36 million.
- The repurchase program is scheduled for a six-month period ending July 30, 2024.
- Repurchases may be funded via existing cash, future cash flow, or proceeds from debt/borrowings.
DocGo Inc. issued a press release in response to a report published by short seller Fuzzy Panda Research. The company's response includes preliminary financial results for the fiscal year 2023.
🚩 Red Flags
- Short seller report (Fuzzy Panda Research) often precedes significant volatility or investigations into accounting practices.
- Company had to issue preliminary financial results in response to external allegations, suggesting potential scrutiny of reported figures.
📋 Key Facts
- The filing was triggered by a report released by short seller Fuzzy Panda Research.
- DocGo issued a press release on January 16, 2024, to respond to these allegations/reports.
- The response includes preliminary financial results for fiscal year 2023.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
DocGo Inc. issued a press release containing preliminary financial results for FY2023 and guidance for FY2024, specifically in response to a short-seller report from Fuzzy Panda Research.
🚩 Red Flags
- Direct response to a short-seller report often indicates significant market volatility or allegations regarding company practices/finances.
- The release of preliminary results in response to external pressure can signal uncertainty in previously reported financial data.
📋 Key Facts
- The filing includes preliminary financial results for fiscal year 2023.
- The company provided select preliminary guidance for fiscal year 2024.
- The disclosure is a direct response to a report issued by short-seller Fuzzy Panda Research on January 9, 2024.
- Information was furnished under Item 7.01 (Regulation FD Disclosure) and not 'filed' for liability purposes under Section 18.